AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04947488 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Bioarginina C
Description: Dietary supplement vials
Study NCT06187376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Herbal Medicine (CHM) supplement
Description: Dropper of tincture by mouth for 12 weeks.
Study NCT06187376 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tincture.
Study NCT05355142 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PM+
Description: 1 Brief introduction to PM+ \& NDA (5 min) Assessment-based review with PSYCHOLOPS (psychopomps psychology ) assessment (10 min) What is PM+ (20 minutes) Understanding Adversity (30 minutes) Stress Management (20 minutes) Closing the meeting (5 minutes)~2 General Review (5 min) Issue management (70 minutes) Stress management (10 minutes) Closing the meeting (5 minutes)~3 General Review (5 minutes) Problem Management (35 minutes) Take action and be consistent (35 minutes) Stress management (10 minutes) Closing the meeting (5 minutes)~4 General Review (5 minutes) Issue Management (20 minutes) Take action and be persistent (20 minutes) Strengthening Social Support (30 minutes) Stress management (10 minutes) Closing the meeting (5 minutes)~5 General Review (20 minutes) Staying Healthy (30 minutes) Imagining how to help someone (20 minutes) Looking ahead (15 minutes) Closing the de-briefing (5 minutes)
Study NCT05815303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: 10mg/kg iv on day 1, every 21 day
Study NCT05815303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m2 iv on day 1, every 21 day
Study NCT05815303 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Oxaliplatin
Description: 130mg/m2 iv on day 1, every 21 day
Study NCT05815303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m2 po bid on day 1 to 14, every 21 day
Study NCT05815303 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Capecitabine
Description: 1000mg/m2 po bid on day 1 to 14, every 21 day
Study NCT06500091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2916 injection + doxorubicin hydrochloride for injection
Description: TQB2916 is a humanized immune gamma globulins 2 (IgG2) monoclonal antibody targeting CD40.~The mechanism of action of doxorubicin is mainly to destroy the DNA structure of tumor cells, thereby killing malignant tumors. It interferes with the DNA synthesis process of cancer cells by targeting DNA and inhibiting enzymes in DNA replication and repair. In addition, doxorubicin can also trigger cross-link breaks in DNA, leading to apoptosis of cancer cells.
Study NCT06500091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2916 injection+penpulimab injection
Description: TQB2916 is a humanized IgG2 monoclonal antibody targeting CD40. Penpulimab injection is a programmed cell death protein 1 (PD-1) immune checkpoint inhibitor.
Study NCT05133635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Patients with the clinical and laboratory diagnosis of cytokine storm will receive methylprednisolone 250 mg for 3 days.
Study NCT05133635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Patients with the clinical and laboratory diagnosis of cytokine storm will receive tocilizumab 400-800 mg for one time.
Study NCT05312034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation of the predictive model for an antimicrobial management program
Description: Firstly it will be used the predictive model as a simulation tool to educate physicians. For three months, physicians will use the model to understand the main factors associated with Gram-positive infection. They will test the model using real-case data previously collected at the hospitals. The model will provide them information such as the probability of that patient having a Gram-positive infection and the proportion of infected patients in that ICU and hospital.~This model will be embedded in an app and a web page to provide real-time guidance on the predicted probability of infection due to Gram-positive agents.~The intervention will be implemented in two selected hospitals, aiming at monthly decreasing the use of broad-spectrum antibiotics while maintaining or reducing the ICU standardized mortality ratio and the standardized resource use.
Study NCT06221163 — intervention group
Intervention type: OTHER
Intervention: collection of biographical and sociological data
Description: collection of biographical and sociological data. Conducting non-directive interviews (life stories) with transgender patients consulting the Reproductive Medicine Department and their volunteer relatives. Patients are given a 'flyer' at the time of their consultation on which the interviewer's contact details are given. They are free to contact the interviewer to find out when and where an interview might take place (outside hospital).
Study NCT05086471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NaviCam SB
Description: Subjects swallow two types of SB capsules approximately 40 minutes apart in a randomized order. During the capsule endoscopy, the doctor can view the small bowel images taken by the capsules in real time.
Study NCT05086471 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PillCam SB3
Description: Subjects swallow two types of SB capsules approximately 40 minutes apart in a randomized order. During the capsule endoscopy, the doctor can view the small bowel images taken by the capsules in real time.
Study NCT05392491 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention. It is an observational study
Study NCT05506761 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound-guided erector spinae plane block
Description: Patients will receive 20 ml plain bupivacaine 0.25 % bolus, then 10 ml per hour plain bupivacaine 0.125 % continuous infusion via ultrasound-guided erector spinae plane block
Study NCT05506761 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound-guided rhomboid intercostal block combined with sub-serratus plane block
Description: Patients will receive 20 ml plain bupivacaine 0.25 % bolus, then 10 ml per hour plain bupivacaine 0.125 % continuous infusion via ultrasound-guided rhomboid intercostal block combined with sub-serratus plane block
Study NCT06222125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0025
Description: HB0025 IV every 2 weeks (q2w)
Study NCT05206526 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dragon Boat
Description: 12 weeks of training, defined by a precise progressive, structured and supervised program divided into 3 weekly sessions of one hour / one hour and a half preparatory to the Dragon Boat activity.
Study NCT05206526 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-based Exercise
Description: 12 weeks of home-based training composed by 10 exercises.
Study NCT04555122 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Distancing Advertisements
Description: Participants will receive 3 types of advertisements to increase social distancing/staying at home.
Study NCT04951687 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ecologic Barrier©
Description: 5x10\^9 CFU/ 2g per day of Ecologic Barrier©
Study NCT04951687 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder
Description: matched placebo
Study NCT04453293 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG (Tokyo 172) vaccine
Description: Freeze-Dried Glutamate Bacillus Calmette-Guérin BCG Vaccine (Japan BCG Laboratory), 0.1 mL given as single dose by intradermal injection over the outer lower aspect of the deltoid region
Study NCT04453293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vaccine diluent, 0.1 mL given as single dose by intradermal injection over the outer lower aspect of the deltoid region
Study NCT05146570 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: D-lactate test
Description: In device-associated meningitis, CSF will be aspirated before, during or after surgery related to the device, according to the standard practice. Lumbar/ventricular punctures (pre-, intra- and/or postoperatively) and external ventricular (EVD) and lumbar drainage (ELD) aspiration will be performed by neurologist or neurosurgeon according to standardized aseptic techniques. In patients with native meningitis, CSF will be aspirated by lumbar puncture, according the standard practice. The D-lactate test will be performed using spectrophotometric enzyme assay according to the manufacturer's instructions (D-Lactate Colorimetric Assay).
Study NCT05146570 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Standard diagnostic tests
Description: In device-associated meningitis, CSF will be aspirated before, during or after surgery related to the device, according to the standard practice. Lumbar/ventricular punctures (pre-, intra- and/or postoperatively) and external ventricular (EVD) and lumbar drainage (ELD) aspiration will be performed by neurologist or neurosurgeon according to standardized aseptic techniques. In patients with native meningitis, CSF will be aspirated by lumbar puncture, according the standard practice. The standard diagnostic tests will be performed according to standard diagnostic laboratory instructions.
Study NCT05148975 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bronchoalveolar lavage fluid diagnostics
Description: Bronchoalveolar lavage fluid diagnostics for superinfection in patients with COVID-19 pneumonia.
Study NCT05838391 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence Guided Daily Radiotherapy Treatment Planning and Delivery
Description: Subjects will receive 54 Gy of radiation delivered 5 day a week for 6 weeks, 30 radiation treatments total. Intensity-Modulated photon radiation therapy will be delivered on a Varian Ethos linear accelerator. Daily image-guided radiation therapy (IGRT) is required. All treatments will have artificial-intelligence (AI) daily adaptations of the radiation plan to optimize the radiation dose to the targeted area and minimize radiation dose to the normal surrounding organs such as the bowel.
Study NCT05838391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin-C
Description: As part of the subjects' treatment, 10 mg/meters squared of Mitomycin C will be administered intravenously (IV-into the vein) on Day 1 and Day 29.
Study NCT05838391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: As part of the subjects' treatment, 1g/meters squared/day for 4 days of 5-Fluorouracil will be administered by continuous infusion on Days 1-4 (for 96 hours) and Days 29-32 (for 96 hours). 5-Fluorouracil or capecitabine will be administered per the physician's discretion.
Study NCT05838391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: As part of the subjects' treatment, 825 mg/meters squared per day, divided into 2 daily doses, will be taken on days of radiotherapy. Capecitabine or 5-FU will be administered per the physician's discretion.
Study NCT05528627 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pectoral Nerve (PECs) block
Description: Pectoral Nerve (PECS) blocks were performed on the side of surgery, using the ultrasound-guided technique 30 min before the implantable cardiac electronic device (pacemaker, implantable cardioverter defibrillator) insertion procedure
Study NCT06467890 — intervention group
Intervention type: BEHAVIORAL
Intervention: Educational programme about vital pulp therapy
Description: An awareness educational material based on the recent AAPD and AAE guidelines on vital pulp therapy will be sent to the participants right after they answer the questionnaire for the first time
Study NCT05156827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB006
Description: TB006 diluted in normal saline, administered through IV infusion over an hour
Study NCT05156827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline administered through IV infusion over an hour
Study NCT04792931 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: description of adult autoimmune myopathies
Description: description of adult autoimmune myopathies
Study NCT06541873 — intervention group
Intervention type: OTHER
Intervention: Clinical and gait evaluation
Description: The dual-task conditions to be assessed during gait performance will include: counting backwards by 3 (executive simple task); counting backwards by 7 (executive complex task); mnemonic recall of the Rey's Auditory Verbal Learning Test (RAVLT). Performance scores will be correlated with cognitive status and clinical features. Data will be collected at the baseline (i.e., only) visit within the enrollment timeframe of 3 years from study initiation.
Study NCT05957172 — intervention group
Intervention type: DEVICE
Intervention: ZOLL Arrhythmia Management System
Description: AMS records rhythm, heart rate, subject-reported symptoms, and multiple parameters that include respiration rate, activity, and body posture (biometric data)
Study NCT06158516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
Study NCT04808856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenocorticotropic Hormone
Description: Adrenocorticotropic Hormone Injection 25u qd iv \*3d
Study NCT04808856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone Injection
Description: Methylprednisolone Injection 40mg qd iv \*3d
Study NCT04409873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral-B Mouth Sore mouthwash
Description: Rinse and gargle 4 times daily, for 60 seconds, for 4 weeks.
Study NCT04409873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crest Pro-Health Multi-Protection mouthwash
Description: Rinse and gargle 4 times daily, for 60 seconds, for 4 weeks.
Study NCT04409873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CloSYS Ultra Sensitive Rinse mouthwash
Description: Rinse and gargle 4 times daily, for 45 seconds, for 4 weeks.
Study NCT04409873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water
Description: Rinse and gargle 4 times daily, for 60 seconds, for 4 weeks.
Study NCT04409873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Listerine Zero Mouthwash Product
Description: Rinse and gargle 4 times daily, for 30 seconds, for 4 weeks.
Study NCT05244850 — intervention group
Intervention type: OTHER
Intervention: Test
Description: Measurements
Study NCT06241612 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Individualized Elective Neck Irradiation
Description: Individualized Elective Neck Irradiation
Study NCT06241612 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Individualized Elective Neck Irradiation
Description: Individualized Elective Neck Irradiation
Study NCT05230888 — intervention group
Intervention type: OTHER
Intervention: Questionnaires about symptoms
Description: The CGA and VES-13 questionnaires will be conducted at baseline. Immune-related adverse events (irAEs) will be investigated at 3 and 6 months using a Patient Knows Best symptom tracker form (local Trust created).
Study NCT04951258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise
Description: The intervention is a 60-minute session, 3 times/week, totaling 9 weeks. Multicomponent exercise included strengthening, balance training, aerobic dance, and stretching
Study NCT04951258 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video home exercise group
Description: The intervention is a 60-minute session, 3 times/week, totaling 9 weeks. Video home exercise included four limbs mobility exercise, stretching, strengthening, and aerobic exercise
Study NCT06158516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle
Study NCT04894929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multi component exercise in the clinic
Description: Patients randomly assigned to this group have a pre-fragile or fragile SPPB condition, so they will perform:~3 days of empowerment work, 4 days of flexibility work, and daily walking aerobic work and balance work.
Study NCT04894929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vestibular exercise in the clinic
Description: Patients randomly assigned to this group have a pre-fragile or fragile SPPB condition, so they will perform. sessions of about 20 minutes with 5 weekly sessions (Monday to Friday) consisting of 5 repetitions without fatigue of:~to. Head and eye movements while sitting. b. Head and body movements while sitting. c. Exercises standing. d. Combined exercises of modifications in steps, unstable surfaces and in progress.~and. Along with push up 30sec and squat 30sec
Study NCT04894929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vestibular exercise at home telerehabilitation
Description: Patients randomly assigned to this group have a pre-fragile or fragile SPPB condition, so they will perform with the help of a video. sessions of about 20 minutes with 5 weekly sessions (Monday to Friday) consisting of 5 repetitions without fatigue of:~to. Head and eye movements while sitting. b. Head and body movements while sitting. c. Exercises standing. d. Combined exercises of modifications in steps, unstable surfaces and in progress.~and. Along with push up 30sec and squat 30sec
Study NCT04894929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multi component exercise at home telerehabilitation
Description: Patients randomly assigned to this group have a pre-fragile or fragile SPPB condition, so they will perform with the help of a video:~3 days of empowerment work, 4 days of flexibility work, and daily walking aerobic work and balance work.
Study NCT06252272 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Biopsy from patients undergoing surgery abdominal.
Description: A small portion (about 10 mm in diameter) of liver tissue was collected macroscopically free from alterations of the parenchyma obtained in the open at the site surgery for primary or secondary liver tumors, for the preparation of cultures of organotypic liver slices.
Study NCT05495555 — intervention group
Intervention type: DEVICE
Intervention: INTREPID® Hybrid tip
Description: INTREPID® Hybrid tip for cataract removal
Study NCT04849780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE Oasys 1-Day
Description: TEST
Study NCT04849780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Habitual Lens
Description: Subjects' own Habitual Lenses
Study NCT04735094 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endobronchial biopsy with the use of a balloon attached to the echo-bronchoscope
Description: A small balloon made of latex can be attached to the tip of echo-bronchoscope which is then inflated with water or saline for better apposition of the echo-endoscope and the airway wall. This may improve ultrasound image quality and aid better visualization of the lymph nodes.
Study NCT03971110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoladex and Casodex
Description: The eligible subjects will receive Casodex 50 mg orally per day in combination with Zoladex 10.8 mg implant subcutaneously as neoadjuvant therapy per 12 weeks for up to 24 weeks.
Study NCT06481761 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double-slot brackets
Description: Miniscrews will be inserted in the buccal alveolar bone between first and second molars bilaterally and ligated to second premolar.~Canine Retraction using Nickel titanium closed-coil springs delivering a force of 150 gram, extending the spring between the canine and first molar hooks.~retraction on double 0.016'' Stainless steel round wires in both slots of the double slot brackets.~Re-activation of the coil spring will be done in the follow up visits to maintain a constant force through the study.
Study NCT06481761 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single-slot brackets
Description: Miniscrews will be inserted in the buccal alveolar bone between first and second molars bilaterally and ligated to second premolar.~Canine Retraction using Nickel titanium closed-coil springs delivering a force of 150 gram, extending the spring between the canine and first molar hooks.~retraction on single 0.017x0.022'' Stainless steel wire. Re-activation of the coil spring will be done in the follow up visits to maintain a constant force through the study.
Study NCT03495986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation Leg Cycle Ergometry
Description: Exercise training will consist of three to five, 40-67 minute sessions (200 minutes at target intensity) each week for a total of 16 weeks at 70% maximal heart rate; 10-minute warm-up and cool-down sessions will accompany each exercise session.
Study NCT06459245 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Bend the dumbbell, holding one dumbbell in each hand, on the side of the body, bend the arm to lift the dumbbell, front wall and upper arm as close as possible, pause for a moment, and then slowly lower the dumbbell until both arms are completely straight The second section of the dumbbell side flat, straight back, feet standing, arms perpendicular to the side of the body, hands grasp the dumbbell, to the side above the shoulder level, elbow slightly bent, and then put back in place The third section of the dumbbell rowing, feet stand straight, hold the dumbbell, the arm as far back as possible, can feel the upper arm and the waist back is stretched, and then straight back into the preparatory position Section 4: Lift the dumbbell flat in front of you, with your feet open, hold the dumbbell with both hands, extend your arms naturally in front of you, lift the dumbbell to the elbow above shoulder height, stay for 1-2 seconds.